Objective. MicroRNAs (miRNAs) play important roles in many biological processes and recent studies have provided growing evidences that miRNA dysregulation might play important roles in the pathogenesis of rheumatoid arthritis (RA). The aim of this study was to investigate the contribution of miRNAs to altered gene expressions in RA. Methods. To investigate whether the differential expression of miRNA in RA could account for the altered expression of certain genes, we compared the different expressions of miRNAs and mRNAs in rheumatoid synovial fluid monocytes with that of normal peripheral blood (PB) monocytes by using a gene expression oligonucleotide microarray and a microRNA microarray. Results. Comparative analysis of the mRNA profiles showed significant different expressions of 430 genes in RA synovial monocytes, of which 303 (70%) were upregulated and 127 (30%) were downregulated, as compared with that of normal PB monocytes. Out of differentially expressed 13 miRNAs, 9 miRNAs were upregulated and 4 miRNAs were downregulated in the RA synovial monocytes. A total of 62 genes were predicted as target genes of the 13 differentially expressed miRNAs in the RA synovial monocytes. Among the 62 miRNA-targeted genes, a few genes such as GSTM1, VIPR1, PADI4, CDA, IL21R, CCL5, IL7R, STAT4, HTRA1 and IL18BP have been reported to be associated with RA. Conclusion. In the present study, we observed that several miRNAs are differentially expressed in RA synovial monocytes, and we suggest that these different expressions of miRNAs may regulate the expression of several genes associated with the pathogenesis of RA.
have shown an increased expression of miR-146a in the human monocytic THP-1 cells in response to TNFα, IL-1β and lipopolysaccharide (LPS) (6) . In that report, miR-146a targets the IL-1 receptor associated kinase 1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6), suggesting that increased miRNA-146a might inhibit the effect of IL-1β as a negative feedback mechanism. Further, the abnormal expression of several miRNAs was reported in patients with RA. Both miR-155 and miR-146a were found to be overexpressed in synovial tissues and in the synovial fibroblasts of patients with RA (7, 8) .
Among them, miR-146a was mainly expressed in the CD68+ monocytes of synovial tissues from RA patients. TNFα, IL-1β and LPS induce the expression of miR-155 in RA synovial fibroblasts, and the enforced expression of miR-155 in RA synovial fibroblasts represses the level of matrix metalloproteinase 3 (MMP-3), suggesting that miR-155 may be involved in the modulation of the tissue damage in RA (8) . The peripheral blood (PB) mononuclear cells from patients with RA exhibit increased expressions of miR-146a, miR-155, miR-132 and miR-16, as compared with that of healthy controls, and high miR-146a and miR-16 expressions are correlated with active disease in patients with RA, suggesting that the levels of the miR-146a and miR-16 expressions may be a useful marker of disease activity in RA (9) . However, the pathogenic roles of miRNAs in RA have been mainly studied in RA synovial fibroblasts, and their roles in monocytes/macrophages have not been well studied.
To examine the abnormal expression of miRNAs in RA synovial monocytes, we compared the different expressions of miRNAs and mRNAs in RA synovial monocytes with that of normal PB monocytes by using a gene expression oligonucleotide microarray and a microRNA microarray. Because synovial monocytes are influenced by inflammatory synovial fluid liberated mainly from synovium of RA, we examined synovial monocytes as cells affected by inflammatory condition of RA. Synovial monocytes are derived mainly from circulating monocytes of PB in RA patients and PB monocytes of RA patients also are exposed to abundant amounts of inflammatory cytokines, therefore, we used PB monocytes of healthy individuals which are exposed to negligible concentrations of inflammatory molecules as a control for synovial monocytes from RA patients. In this study, we found that several miRNAs are differentially expressed in RA synovial monocytes as compared to PB monocytes of healthy individuals, and we suggest that these miRNAs may cause misregulation of important genes involved in the pathogenesis of RA. Table 1 . This study protocol was approved by IRB of the Hospital for Rheumatic Disease, Hanyang University and we got written informed consents from all participated patients.
Materials and Methods

Cell isolation
mRNA expression profiling
The total RNA was extracted from isolated cells (two healthy donors and six RA patients (RA1-RA6)) using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction. For quality control, the RNA purity and integrity were evaluated by performing denaturing gel electrophoresis and using the OD 260/280 ratio, and the RNA was 
8). T-tests and fold changes
were applied for searching for significant genes. Statistical significance was adjusted by the Benjamini-Hocbherg multiple-testing correction with the false discovery rate (FDR) at 5%. Hierarchical cluster analysis was performed using complete linkage and the Euclidean distance as a measure of similarity.
MicroRNA expression profiling
We performed miRNA expression profiling in the same set of samples (two healthy donors and six RA patients (RA1-RA6)) that were used in the analysis of mRNA microarray. Foster City, CA, USA). The expression of the tested miRNAs was normalized relative to the levels of the RNU44 controls.
Statistics
Statistically significant differences of the miRNA and mRNA expressions between the two groups were determined with the Mann-Whitney test. p-values less than 0.05 were considered significant.
Results
Differentially expressed microRNAs in the RA synovial monocytes compared to the normal PB monocytes
To examine the difference of the miRNA expression between the RA synovial monocytes and normal PB monocytes, we used the Illumina microRNA expression profiling assay. We identified fourteen differentially expressed miRNAs in the RA synovial monocytes as compared with that of the normal PB monocytes (Fig. 1) . A significant difference was defined as a 2-fold change and a p-value＜0.05. Among the miRNAs that were differentially expressed in the RA synovial monocytes, HS_194 is a novel miRNA that is not described in the miRBase database (10). We cannot map the possible target genes of this novel HS_194 using miRBase, so this miRNA was excluded from the analysis of miRNA-target gene pairing. CD33  TRAF3IP3  PISD  CD300LF  NME3  TRAF3IP3  VIPR1  GSTM2  GSTM1  IL11RA  TESC  SCPEP1  TRAF3IP3  CD52  IL11RA  NME3  CDA  ZNF467  TRAF3IP3  PADI4  CSTA  NFE2  CD33  SCPEP1  CD300LF  GSTM2  C14orf159  ALDH1A1  GSTM2  C6orf192  SLC44A2  CDH23  PISD  CIDEB  YPEL3  PISD  GSTM2  CD79B   GSTM1  CFP  ATG16L2  IL11RA ADFP  ANKRD9  COLEC12  IDS  IL21R  MGAT4A   NEK6  PRDX1  SMAD6  ANKRD37  ANTXR1  BCAR3  CCL5  DHRS3  GPRIN3  IL7R  OLFML2B  STAT4  ZMYND15  ADAMDEC1  AVPI1  BAG3  MRAS  P4HA2   PHACTR1  PRDX1  YWHAH   BCAT1  C17orf58  FASN  HTRA1  IL18BP  P4HA2   PEA15  TMEM51 To further explorer the biologic importance of these differ- hsa-miR-125a-3p, hsa-miR-92b* hsa-miR-125a-3p hsa-miR-34a hsa-miR-34a hsa-miR-487b hsa-miR-335* hsa-miR-335* hsa-miR-335* hsa-miR-495 hsa-miR-495
The presence of a functional allele for GSTM1 associated with a reduced risk of RA Deficient expression in RA patients associated with the predominant proinflammatory Th1 milieu Citrullination of selected substrates may end up in dampening of inflammation at the sites of PAD activity PAD4 contributes to the generation of ACPA specific substrates and is itself a target of autoantibodies in RA. Cytidine deaminase levels are raised in serum and synovial fluid in rheumatoid arthritis (RA)
IL-21R is expressed in RA synovium by RASFs and synovial macrophages RANTES is overexpressed in RA SF Enhanced expression of IL-7Ralpha in RA patients contributes significantly to the joint inflammation STAT4, and Jak3 protein expression was generally increased in inflammatory arthritis A haplotype of STAT4 is associated with increased risk for both rheumatoid arthritis HtrA1 contributes to the destruction of extracellular matrix through both direct and indirect mechanisms IL18BP levels were raised in RA To verify the microarray results of miRNAs, expressions of hsa-miR-34a and hsa-miR-125a-3p were examined by quantitative real-time PCR. Until now, functions of miRNAs are not extensively studied. For validation of microarray results, hsa-miR-34a and hsa-miR-125a-3p were selected because these two miRNAs were relatively well studied in their biologic functions. The expression of hsa-miR-34a and hsa-miR-125a-3p were significantly up-regulated in the RA synovial monocytes compared with that of the normal PB monocytes (Fig. 2B ).
Discussion
In this study, we examined the involvement of differentially Recent studies have demonstrated dysregulated expression of Also recent study revealed that let-7e repressed Toll-like receptor 4 (TLR4) in macrophages, indicating that the response of macrophages to LPS can be modulated by let-7e (41) .
In this study, we predict that several genes related with the pathogenesis of RA, including GSTM1, VIPR1, PADI4, CDA, IL21R, CCL5, IL7R, STAT4, HTRA1 and IL18BP, are targets of the differentially expressed miRNAs in the RA synovial monocytes, and so we suggest that miR-125a-3p, miR-92b*, miR-34a, miR-487b, miR-335* and miR-495 may play important roles in the pathogenesis of RA. However, integrated analysis of miRNAs and mRNAs using a prediction algorithm such as MicroCosm Targets Version 5 is not yet perfect to investigate the interaction of miRNAs and their target genes due to the inaccuracies in the algorithm of miRNA target prediction and also due to other mechanisms of miRNA such as translational inhibition, which is impossible to detect using a mRNA microarray. Also the low number of samples analysed (2 controls and 6 cases in the microarray studies, and 4 controls and 12 cases in the replication study) is a major limitation in this study.
In the present study, we observed that several miRNAs are differentially expressed in RA synovial monocytes, and we suggest that these altered miRNAs may regulate the expression of several genes associated with the pathogenesis of RA. In this study, we provide a systematic approach for investigating the miRNA-regulated gene expression profile in rheumatic diseases such as RA. In addition to the integrated analysis of miRNAs and mRNA used in the present study, a future study that uses genetic manipulation such as the deletion or over-expression of miRNAs will provide further evidence that these altered miRNAs play important roles in the pathogenesis of RA.
Conclusion
